AAM Statement on CMS's Proposed Rule Requiring Generic Drugs to be Covered on Generic Tiers

WASHINGTON D.C. (December 13, 2022) -- The Association for Accessible Medicines (AAM) commends the Centers for Medicare & Medicaid Services (CMS) for their proposal requiring generic drugs to be covered on generic tiers.

"This common-sense approach will result in meaningful savings for America’s patients," said David Gaugh, Interim CEO of AAM. "As CMS notes, ‘it is reasonable to assume that consumers expect that only generic drugs are covered at the cost-sharing amount in the generic drug cost-sharing tier.’ Not only is this a reasonable assumption, but it is an important step to ensuring that patients are not forced to overpay for low-cost generics. AAM looks forward to working with the Agency to finalize this proposal.”

Susan Reilly
Director of Communications, AAM

About AAM

AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 91 percent of prescriptions dispensed in the U.S. but only 18 percent of total drug spending.


Association for Accessible Medicines


Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.